{
    "nctId": "NCT03606369",
    "briefTitle": "Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.",
    "officialTitle": "Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Neoplasm, Antineoplastic Agents, Antiemetics, Quality of Life",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2, PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 560,
    "primaryOutcomeMeasure": "Acute nausea control",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients 18 years old or more.\n* Not metastatic breast cancer confirmed with biopsy.\n* Candidates to receive chemotherapy with anthracyclines combined with cyclophosphamide or carboplatin combined with docetaxel or docetaxel combined with cyclophosphamide.\n* No previous treatment with radiotherapy or chemotherapy.\n* Adequate hematologic function (Hb \\>10 gr/dl, neutrophils \\>1500, platelets \\>100,000,) renal (Creatinine \\<1.2 or creatinine depuration \\>60 ml/min), hepatic (liver enzymes \\<2.5 their normal value) and cardiologic (electrocardiogram).\n* Adequate physical state (ECOG 0-1)\n* Patients that accept to enter in protocol and sign the informed consent.\n\nExclusion Criteria:\n\n* Prolonged QT (\\>480 mseg)\n* Comorbidities of the airway\n* Intolerance to swallow medications",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}